Edition:
United States

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

4.48USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$4.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
69,221
52-wk High
$5.13
52-wk Low
$1.79

Chart for

About

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $158.25
Shares Outstanding(Mil.): 37.32
Dividend: --
Yield (%): --

Financials

  MEIP.OQ Industry Sector
P/E (TTM): -- 241.68 34.14
EPS (TTM): -1.04 -- --
ROI: -88.27 -5.91 13.17
ROE: -88.27 -7.75 15.14

BRIEF-MEI Pharma And Helsinn Announce Positive Results In Myelodysplastic Syndrome Trial

* MEI PHARMA AND HELSINN GROUP ANNOUNCE SUCCESSFUL INTERIM ANALYSIS OF PRACINOSTAT/AZACITIDINE PHASE 2 COMBINATION STUDY IN HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS

May 31 2018

BRIEF-Growth Equity Opportunities Fund V LLC Reports 9.99 Pct Stake In MEI Pharma Inc

* GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 9.99 PERCENT STAKE IN MEI PHARMA INC AS OF MAY 16 - SEC FILING Source text: (https://bit.ly/2IHP4lE) Further company coverage:

May 23 2018

BRIEF-MEI Pharma Announces $75 Mln Private Placement

* MEI PHARMA INC - PROCEEDS FROM FINANCING WILL BE USED TO FUND CONTINUED CLINICAL DEVELOPMENT OF MEI-401

May 14 2018

BRIEF-MEI Pharma Q3 Loss Per Share $0.16

* Q3 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S

May 09 2018

BRIEF-Mei Pharma Inc says ‍On Feb 22, Board Voted To Increase Size Of Board By One Seat

* MEI PHARMA INC - ‍ON FEBRUARY 22, 2018, BOARD OF CO VOTED TO INCREASE SIZE OF BOARD BY ONE SEAT -SEC FILING​ Source text - (http://bit.ly/2EUshBn) Further company coverage:

Feb 26 2018

BRIEF-MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study

* MEI PHARMA INTERIM DATA REVIEW SUPPORTS CONTINUATION OF CLINICAL STUDY EVALUATING ME-344 IN PATIENTS WITH BREAST CANCER

Feb 13 2018

BRIEF-MEI Pharma Q2 Loss Per Share $0.16

* ‍AS OF DECEMBER 31, 2017, HAD $42.4 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS, WITH NO OUTSTANDING DEBT​

Feb 08 2018

BRIEF-Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency

* HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

Jan 11 2018

BRIEF-MEI Pharma Announces FDA Clearance Of Investigational New Drug Application For CDK Inhibitor Voruciclib

* MEI PHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CDK INHIBITOR VORUCICLIB

Jan 08 2018

Earnings vs. Estimates